...
首页> 外文期刊>BJU international >A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.
【24h】

A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.

机译:扩大前列腺采样时代中低级和中级前列腺癌患者预后升级的列线图。

获取原文
获取原文并翻译 | 示例
           

摘要

Study Type - Diagnostic (exploratory cohort) Level of Evidence 2b. OBJECTIVE: To develop a nomogram to predict the probability that the pathological Gleason sum (GS) will be higher than that indicated by the biopsy, suggesting a higher risk for the patient presumed to be at low risk, as a substantial proportion of patients with low and intermediate grade on biopsy are upgraded on interpretation of the radical prostatectomy (RP) specimens, but a similar clarification of accurate Gleason scoring is not available in patients with no surgical histology. PATIENTS AND METHODS: The study included 1017 patients who had RP after biopsy showing GS 6 and 7 (3 + 4) from 2000 to 2007. Nomogram predictor variables included age, race, digital rectal examination, prostate-specific antigen (PSA) level, number of cores taken, number of positive cores, maximum percentage cancer in any core, number of previous biopsies, prostate volume, clinical stage, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, inflammation and perineural invasion. We calculated the nomogram-predicted probability in each patient. The area under the receiver operating characteristic curve was calculated as a measure of discrimination, and the calibration was assessed graphically. RESULTS: The mean age of the patients was 60 years, the mean PSA level 6.62 ng/mL; 336 patients were upgraded (33%), 623 remained the same (61.3%) and 58 were downgraded (5.7%). A nomogram for predicting the possibility of upgrading was constructed that had a concordance index of 0.68. The nomogram was well calibrated. CONCLUSIONS: Our nomogram for predicting upgrading provides important additional information for deciding on treatment to both the urologist and the patient with low- and intermediate-grade prostate cancer. It might prove useful when the possibility of a more aggressive Gleason variant can change the management, and is especially meaningful when management options other than surgery are selected based on the inability to recognize the true pathological actual GS.
机译:研究类型-诊断(探索性队列)证据水平2b。目的:开发诺模图以预测病理性格里森和(GS)高于活检所表明的可能性,这表明假定为低风险的患者的风险较高,因为低比例的患者占很大比例根治性前列腺切除术(RP)标本的解释使活检和中级活检等级得到了提高,但是对于没有手术组织学的患者,没有类似的澄清精确的Gleason评分的说明。患者与方法:该研究包括2000年至2007年1017例活检后表现为GS 6和7(3 + 4)的RP患者。诺法图预测变量包括年龄,种族,直肠指检,前列腺特异性抗原(PSA)水平,所取核心的数量,阳性核心的数量,任何核心的最大癌症百分率,既往活检数量,前列腺体积,临床分期,高度前列腺上皮内瘤变,非典型小腺泡增生,炎症和神经周浸润。我们计算了每位患者的诺模图预测概率。计算接收器工作特性曲线下的面积作为判别的度量,并以图形方式评估校准。结果:患者的平均年龄为60岁,平均PSA水平为6.62 ng / mL。升级了336例患者(33%),保持不变的623例(61.3%),降级了58例(5.7%)。构造了一个预测升级可能性的列线图,其一致性指数为0.68。列线图已很好地校准。结论:我们的诺模图用于预测升级,为泌尿科医师和中低度前列腺癌患者的治疗决策提供了重要的附加信息。当更具侵略性的格里森(Gleason)变异可能改变治疗方法时,它可能被证明是有用的;当基于无法识别真正的病理性实际GS而选择了除手术以外的治疗方法时,这尤其有意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号